Aptus Pharma Limited has submitted a clarification letter to BSE Limited regarding typographical errors in its previous disclosure about the Board of Directors meeting held on Saturday, August 08, 2026.
The clarification addresses two specific errors:
1. Venue Correction: The opening paragraph of the original letter incorrectly stated the meeting venue as "the registered office of the Company" instead of the correct venue: "the Head Office of the Company situated at RK Trade Tower, Wing A, Office Nos. 616 to 619, Near Sheetal Park Circle, 150 Feet Ring Road, Rajkot, Gujarat, India – 360006."
2. Annexure Title Correction: The annexure referred to as "Annexure A" under Point No. 1 of the original letter was inadvertently titled "Annexure 1" in the annexure document itself. The title should be read as "Annexure A."
The company confirms that these errors are purely typographical in nature and do not affect the substance, decisions, or outcomes of any resolutions passed or matters considered by the Board of Directors during the meeting.
The letter is signed by Tejas Hathi, Managing Director (DIN: 03151221), and digitally signed by Hathi Tejash Maheshchandra on August 10, 2026, at 12:46:58 +05:30.
The company has requested BSE Limited to take this clarification on record and read the original disclosure with the stated corrections.
Financial Impact
No financial impact disclosed. The clarification pertains solely to typographical corrections in the meeting disclosure.